Safety dashboard
Metabolic peptide safety signal dashboard
Curated single-page dashboard of all metabolic peptide safety signals: GI events, pancreatitis, gallbladder disease, retinopathy, thyroid C-cell warning, hypoglycaemia, psychiatric signal tracking, pregnancy / breastfeeding, lean-mass risk, dehydration / renal risk and counterfeit-product risk. Signal maturity, implicated molecule classes and links to the detailed signal pages.
One-page view of every safety signal tracked across the metabolic peptide landscape. Each row is editorially curated from the signal's detail page; click through for what is known, what remains uncertain, the trial limitations and the UK pharmacovigilance framing.
| Signal | Maturity | Implicated classes | Headline framing |
|---|---|---|---|
| GLP-1 class gastrointestinal adverse events | Well-characterised class effect | GLP-1 mono-agonists, Dual GLP-1/GIP agonists, Triple GLP-1/GIP/glucagon agonists, Amylin combinations (e.g., CagriSema) | Nausea, diarrhoea, constipation, vomiting and abdominal pain are the most common adverse events reported with GLP-1 receptor agonists and dual / triple agonists. They tend to be mild-to-moderate, concentrated during titration, and improve over time, but are also the leading reason for treatment discontinuation in trials. |
| Pancreatitis signal | Monitored signal, evolving evidence | GLP-1 mono-agonists, Dual GLP-1/GIP agonists, Triple agonists | Acute pancreatitis has been reported in association with GLP-1 receptor agonists since the earliest agents in the class. Pivotal trials and post-marketing surveillance describe a small but non-zero rate, the signal continues to be monitored, and personal or family history of pancreatitis is a contraindication or warning in the licensed product information for the major agents. |
| Gallbladder disease in the context of rapid weight reduction | Well-characterised class effect | GLP-1 mono-agonists, Dual GLP-1/GIP agonists | Cholelithiasis and cholecystitis events have been reported more frequently with GLP-1 receptor agonists than placebo in pivotal trials, consistent with the well-known association between rapid weight loss and gallstone formation. |
| Diabetic retinopathy and rapid HbA1c reduction | Monitored signal, evolving evidence | GLP-1 mono-agonists, Dual GLP-1/GIP agonists | Rapid HbA1c reduction in adults with pre-existing diabetic retinopathy has been associated with transient worsening of retinopathy in some trials. The SUSTAIN 6 cardiovascular outcomes trial of semaglutide reported an imbalance in retinopathy complications and prompted ongoing investigation. |
| Thyroid C-cell warning explained | Monitored signal, evolving evidence | GLP-1 mono-agonists, Dual GLP-1/GIP agonists, Triple agonists | GLP-1 receptor agonist labelling carries a boxed warning (US FDA) regarding medullary thyroid carcinoma based on rodent C-cell tumour findings. Translation to humans remains uncertain; long-term human evidence has not established a causal association. |
| Hypoglycaemia risk by drug class | Well-characterised class effect | GLP-1 mono-agonists, Dual GLP-1/GIP agonists, Triple agonists | On their own, GLP-1 receptor agonists at licensed doses cause hypoglycaemia infrequently because their insulinotropic effect is glucose-dependent. Risk rises substantially when combined with insulin or sulfonylureas. |
| Psychiatric adverse-event signal tracking | Active pharmacovigilance review | GLP-1 mono-agonists, Dual GLP-1/GIP agonists | Concerns about mood-related and suicidality signals with GLP-1 receptor agonists have been the subject of EMA and FDA reviews. Current published reviews have not established a causal psychiatric safety signal but active pharmacovigilance continues. |
| Pregnancy and breastfeeding exclusions | Well-characterised class effect | GLP-1 mono-agonists, Dual GLP-1/GIP agonists, Triple agonists | Licensed incretin medicines are not recommended in pregnancy or breastfeeding in their UK SmPCs. Trials systematically exclude pregnant and breastfeeding participants. |
| Injection-site reactions in clinical trials | Well-characterised class effect | All subcutaneous incretin medicines | Injection-site reactions (erythema, induration, pruritus) are common with subcutaneous peptide therapies but are typically mild and self-limiting in pivotal trials. |
| Lean-mass and nutritional risk during rapid weight reduction | Monitored signal, evolving evidence | GLP-1 mono-agonists, Dual GLP-1/GIP agonists, Triple agonists | Substantial weight reduction with incretin therapy includes loss of lean mass alongside fat mass. In older adults, sarcopenic obesity, and those with limited protein intake, the lean-mass dimension warrants explicit attention. |
| Dehydration and renal risk | Well-characterised class effect | GLP-1 mono-agonists, Dual GLP-1/GIP agonists, Triple agonists | Severe vomiting or diarrhoea on incretin therapy can precipitate dehydration, which may worsen renal function — particularly in those with pre-existing chronic kidney disease, on diuretics, or on RAAS-acting medicines. |
| Counterfeit and unregulated products | Risk associated with product quality / supply chain | All affected medicines and research-only peptides | Counterfeit weight-loss pens, mislabelled vials and grey-market compounded products have been the subject of MHRA enforcement and public warnings. Risks include unknown identity, purity, sterility, dosing accuracy and the absence of regulated pharmacovigilance. |
Source: editorially curated from /safety signal pages. Each signal page links to the original trial publications, regulator statements and relevant UK pharmacovigilance pathways.
What this dashboard does not do
- It does not triage individual symptoms — that is the role of qualified clinical care.
- It does not list every reportable adverse event from every trial.
- Population-level signals do not establish individual-level risk for any specific patient.
- Headline framing is editorial summary; the original publications are the authoritative reference.
Related UK regulatory topics
Last reviewed 21 May 2026 · safety signal dashboard · Metabolic Peptides editorial team